Corcept Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
730
- Stock Symbol
-
CORT
- Share Price
-
$63.66
- (As of Friday Closing)
Corcept Therapeutics General Information
Description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Contact Information
Website
corcept.comCorporate Office
- 101 Redwood Shores Parkway
- Redwood City, CA 94065
- United States
Corporate Office
- 101 Redwood Shores Parkway
- Redwood City, CA 94065
- United States
Corcept Therapeutics Stock Performance
As of 20-Nov-2026, Corcept Therapeutics’s stock price is $63.66. Its current market cap is $6.96B with 109M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $63.66 | $64.92 | $28.66 - $126.38 | $6.96B | 109M | 1.26M | $1.51 |
Corcept Therapeutics Financials Summary
As of 30-Sep-2026, Corcept Therapeutics has a trailing 12-month revenue of $964M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 12,157,402 | 3,245,225 | 4,906,074 | 2,993,082 |
| Revenue | 963,647 | 761,407 | 675,040 | 482,375 |
| EBITDA | 113,879 | 46,687 | 138,287 | 109,644 |
| Net Income | 162,292 | 99,652 | 141,209 | 106,140 |
| Total Assets | 1,034,027 | 836,651 | 840,553 | 621,517 |
| Total Debt | 8,991 | 6,107 | 6,936 | 151 |
Corcept Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corcept Therapeutics Comparisons
Industry
Financing
Details
Corcept Therapeutics Competitors (52)
One of Corcept Therapeutics’s 52 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Esperion Therapeutics | Private Equity-Backed | Ann Arbor, MI |
Corcept Therapeutics Patents
Corcept Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026059904-A1 | Concomitant administration of cyp3a4 inducers and mifepristone | Pending | 10-Sep-2024 | ||
| US-20260069586-A1 | Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome | Pending | 10-Sep-2024 | ||
| WO-2026059903-A1 | Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome | Pending | 10-Sep-2024 | ||
| WO-2025265030-A1 | Concomitant administration of selective glucocorticoid receptor modulator relacorilant and p-glycoprotein substrates | Pending | 21-Jun-2024 | ||
| WO-2025265030-A9 | Concomitant administration of selective glucocorticoid receptor modulator relacorilant and p-glycoprotein substrates | Pending | 21-Jun-2024 | A61P3/10 |
Corcept Therapeutics Signals
Corcept Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
33.99 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Corcept Therapeutics FAQs
-
When was Corcept Therapeutics founded?
Corcept Therapeutics was founded in 1998.
-
Where is Corcept Therapeutics headquartered?
Corcept Therapeutics is headquartered in Redwood City, CA.
-
What is the size of Corcept Therapeutics?
Corcept Therapeutics has 730 total employees.
-
What industry is Corcept Therapeutics in?
Corcept Therapeutics’s primary industry is Pharmaceuticals.
-
Is Corcept Therapeutics a private or public company?
Corcept Therapeutics is a Public company.
-
What is Corcept Therapeutics’s stock symbol?
The ticker symbol for Corcept Therapeutics is CORT.
-
What is the current stock price of Corcept Therapeutics?
As of 20-Nov-2026 the stock price of Corcept Therapeutics is $63.66.
-
What is the current market cap of Corcept Therapeutics?
The current market capitalization of Corcept Therapeutics is $6.96B.
-
What is Corcept Therapeutics’s current revenue?
The trailing twelve month revenue for Corcept Therapeutics is $964M.
-
Who are Corcept Therapeutics’s competitors?
Arrowhead Pharmaceuticals, Cytokinetics, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Esperion Therapeutics are some of the 52 competitors of Corcept Therapeutics.
-
What is Corcept Therapeutics’s annual earnings per share (EPS)?
Corcept Therapeutics’s EPS for 12 months was $1.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process